eNOS Pharmaceuticals, Inc. has developed a prophylactic therapy which enhances the vascular system’s capacity to vasodilate upon demand without reduction in blood pressure. This therapy is a patented combination of statin and L-arginine. The effect of this therapy ameliorates the debilitating consequences of conditions that result in decreased blood flow such as myocardial infarction (MI), intermittent claudication and stroke. eNOS has entered into strategic alliances with, first, Elan Pharmaceuticals, and, then Thorne Pharmaceuticals.
|
